{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T15:36:45Z","timestamp":1778254605023,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.msard.2024.105667","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T16:37:59Z","timestamp":1715099879000},"page":"105667","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Intact natalizumab pharmacokinetics is impacted by endogenous IgG4 concentration"],"prefix":"10.1016","volume":"87","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2538-5819","authenticated-orcid":false,"given":"Lesley J.","family":"Page","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iona F.","family":"Pay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward T.","family":"Castellana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphaela","family":"Heussen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Hoyt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Foley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley T.","family":"Messmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2024.105667_bib0001","series-title":"Tysabri Prescribing Information","year":"2017"},{"key":"10.1016\/j.msard.2024.105667_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104713","article-title":"Natalizumab treatment of multiple sclerosis \u2014 a Danish nationwide study with 13 years of follow-up","volume":"74","author":"Buron","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105667_bib0003","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0149330","article-title":"Serum concentrations of IgG4 in the Spanish adult population: relationship with age, gender, and atopy","volume":"11","author":"Carballo","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.msard.2024.105667_bib0004","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/NXI.0000000000000388","article-title":"\u03914-integrin receptor desaturation and disease activity return after natalizumab cessation","volume":"4","author":"Derfuss","year":"2017","journal-title":"Neurol. Neuroimmunol. NeuroInflammation"},{"key":"10.1016\/j.msard.2024.105667_bib0005","first-page":"1","article-title":"Progressive multifocal leukoencephalopathy with natalizumab extended or standard interval dosing in the United States and the rest of the world","volume":"00","author":"Dsilva","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.msard.2024.105667_bib0006","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.80.7_supplement.S30.002","article-title":"Natalizumab related PML: an evolving risk stratification paradigm (S30.002)","volume":"80","author":"Foley","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105667_bib0007","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/S1474-4422(22)00143-0","article-title":"Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial","volume":"21","author":"Foley","year":"2022","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2024.105667_bib0008","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.msard.2019.03.017","article-title":"Evaluation of natalizumab pharmacokinetics and pharmacodynamics with standard and extended interval dosing","volume":"31","author":"Foley","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2024.105667_bib0009","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1007\/s00415-011-6116-8","article-title":"Progressive multifocal leukoencephalopathy and natalizumab","volume":"258","author":"Hellwig","year":"2011","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2024.105667_bib0010","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1212\/01.wnl.0000341766.59028.9d","article-title":"Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function","volume":"72","author":"Khatri","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105667_bib0011","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange","volume":"317","author":"Kolfschoten","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.msard.2024.105667_bib0012","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nbt.1553","article-title":"Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo","volume":"27","author":"Labrijn","year":"2009","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.msard.2024.105667_bib0013","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/jcph.894","article-title":"Population pharmacokinetics and target engagement of natalizumab in patients with multiple sclerosis","volume":"57","author":"Muralidharan","year":"2017","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.msard.2024.105667_bib0014","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/ana.20859","article-title":"Natalizumab effects on immune cell responses in multiple sclerosis","volume":"59","author":"Niino","year":"2006","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2024.105667_bib0015","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2144\/btn-2022-0106","article-title":"Accurate prediction of serum antibody levels from noninvasive saliva\/nasal samples","volume":"74","author":"Page","year":"2023","journal-title":"BioTechniques"},{"key":"10.1016\/j.msard.2024.105667_bib0016","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1097\/FTD.0000000000001038","article-title":"Peptide mimotope-enabled quantification of natalizumab arm exchange during multiple sclerosis treatment","volume":"45","author":"Page","year":"2023","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.msard.2024.105667_bib0017","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1212\/01.WNL.0000158329.30470.D0","article-title":"Anti-\u03b14 integrin therapy for multiple sclerosis: mechanisms and rationale","volume":"64","author":"Rice","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105667_bib0018","doi-asserted-by":"crossref","first-page":"14473","DOI":"10.1038\/s41598-018-32832-1","article-title":"Identification of peptide mimotope ligands for natalizumab","volume":"8","author":"Ruff","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.msard.2024.105667_bib0019","doi-asserted-by":"crossref","first-page":"e1452","DOI":"10.1212\/WNL.0000000000008243","article-title":"Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing","volume":"93","author":"Ryerson","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2024.105667_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.716548","article-title":"Evaluation of natalizumab pharmacokinetics and pharmacodynamics: toward individualized doses","volume":"12","author":"Serra L\u00f3pez-Matencio","year":"2021","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2024.105667_bib0021","first-page":"1","article-title":"High levels of endothelial ICAM-1 prohibit abrogation of CD4+ T-cell arrest on the inflamed BBB by extended interval dosing of natalizumab","author":"Soldati","year":"2023","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.msard.2024.105667_bib0022","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1177\/13524585221136448","article-title":"Fingerprick blood samples to measure serum natalizumab concentrations","volume":"29","author":"Toorop","year":"2023","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2024.105667_bib0023","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1177\/1352458516684023","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy is not preceded by elevated drug concentrations","volume":"23","author":"van Kempen","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2024.105667_bib0024","article-title":"Extended dosing of monoclonal antibodies in multiple sclerosis","author":"van Kempen","year":"2021","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.msard.2024.105667_bib0025","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1111\/bjh.14158","article-title":"VLA-4 blockade by natalizumab inhibits sickle reticulocyte and leucocyte adhesion during simulated blood flow","volume":"174","author":"White","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.msard.2024.105667_bib0026","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/356063a0","article-title":"Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin","volume":"356","author":"Yednock","year":"1992","journal-title":"Nature"},{"key":"10.1016\/j.msard.2024.105667_bib0027","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa054693","article-title":"Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy","volume":"354","author":"Yousry","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2024.105667_bib0028","doi-asserted-by":"crossref","first-page":"32314","DOI":"10.1074\/jbc.M113.501668","article-title":"How natalizumab binds and antagonizes \u03b14 integrins","volume":"288","author":"Yu","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.msard.2024.105667_bib0029","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1136\/jnnp-2015-312940","article-title":"Extended interval dosing of natalizumab in multiple sclerosis","volume":"87","author":"Zhovtis Ryerson","year":"2016","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482400244X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482400244X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T12:06:43Z","timestamp":1720872403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482400244X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":29,"alternative-id":["S221103482400244X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105667","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intact natalizumab pharmacokinetics is impacted by endogenous IgG4 concentration","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105667","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"105667"}}